← Back to Search

Myosin Inhibitor

Mavacamten for Hypertrophic Cardiomyopathy

Phase 3
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of HCM
Presence of LVOT obstruction
Screening 3 weeks
Treatment Varies
Follow Up at day 1 and week 11
Awards & highlights

Study Summary

This trial aims to test how well mavacamten works, how safe it is, and how the body processes it in teenagers with a specific heart condition called obstructive hypertrophic cardiomyopathy.

Who is the study for?
This trial is for adolescents with obstructive hypertrophic cardiomyopathy (HCM) who show symptoms. Specific details about eligibility criteria are not provided, but typically participants must meet certain health standards and may be required to have a specific level of disease severity.Check my eligibility
What is being tested?
The study tests the effectiveness and safety of a drug called Mavacamten compared to a placebo in young patients with HCM. It also looks at how the body processes the drug.See study design
What are the potential side effects?
While specific side effects are not listed, common ones for heart medications like Mavacamten could include dizziness, changes in blood pressure or heart rhythm, fatigue, and potential liver enzyme abnormalities.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have been diagnosed with hypertrophic cardiomyopathy (HCM).
My heart has a blockage in the outflow tract.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at day 1 and week 11
This trial's timeline: 3 weeks for screening, Varies for treatment, and at day 1 and week 11 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in Valsalva left ventricular outflow tract (LVOT) (VLVOT) gradient
Secondary outcome measures
Area under the concentration-time curve (AUC)
Change from baseline in electrocardiogram (ECG) (QT interval)
Change from baseline in maximal wall thickness
+16 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: PlaceboExperimental Treatment1 Intervention
Participants assigned to this arm will receive mavacamten from week 28 to end of treatment at week 56.
Group II: MavacamtenExperimental Treatment1 Intervention
Participants assigned to this arm will receive mavacamten from day 1 to end of treatment at week 56.
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3
Completed Phase 1

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,638 Previous Clinical Trials
4,128,474 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the eligibility criteria for individuals to participate in this clinical study?

"Patients aged between 12 and 17 with a confirmed diagnosis of hypertrophic cardiomyopathy are eligible for enrollment in this study, which aims to recruit 40 participants."

Answered by AI

Are new participants currently being enrolled in this ongoing medical study?

"As documented on clinicaltrials.gov, the ongoing medical trial is not in active pursuit of participants. The trial was first made public on February 15th, 2024 and had its latest update on February 2nd, 2024. Despite this specific study no longer seeking volunteers, there are currently 239 alternative trials actively enrolling patients."

Answered by AI

Do individuals younger than 35 years meet the criteria for participating in this study?

"Participants aged between 12 and 17 are sought for enrollment in this clinical study. There is a total of 30 investigations targeting individuals under the age of legal adulthood, while there are 208 trials designated for those above 65 years old."

Answered by AI

Has Mavacamten been granted approval by the FDA?

"Our team at Power has appraised the safety of Mavacamten as a 3 on our scale, aligning with this being a Phase 3 trial where efficacy data is present alongside multiple iterations of safety data."

Answered by AI
~27 spots leftby Feb 2028